Isoprinosine pills 500mg №20

Isoprinosine

Clinico-pharmacological group

Immunostimulating drug

Mechanism of action

Immunostimulating drug with antiviral action. Isoprinosine is a synthetic complex derivative of purine, which has immunostimulating activity and nonspecific antiviral effect. Restores lymphocyte function under immunodepression conditions, increases blastogenesis in a population of monocytic cells, stimulates the expression of membrane receptors on the surface of T-helper cells, prevents a decrease in the activity of lymphocytic cells under the influence of glucocorticosteroids, and normalizes the inclusion of thymidine in them. Isoprinosine has a stimulating effect on the activity of cytotoxic T-lymphocytes and natural killer cells, the function of T-suppressors and T-helper cells, increases the production of IgG, Interferon gamma, interleukins (IL) -1 and IL-2, reduces the formation of pro-inflammatory cytokines - IL-4 and IL-10, potentiates the chemotaxis of neutrophils, monocytes and macrophages.

The drug exhibits antiviral activity in vivo against Herpes simplex viruses, cytomegalovirus and measles virus, human type III T-cell lymphoma virus, polioviruses, influenza A and B, the ECHO-virus (human enterocytopathogenic virus), encephalomyocarditis and equine encephalitis.The mechanism of antiviral action of izoprinozin is associated with inhibition of viral RNA and the enzyme dihydropteroate synthetase, which is involved in the replication of certain viruses, enhances viral-suppressed lymphocyte mRNA synthesis, which is accompanied by suppression of viral RNA biosynthesis and translation of viral proteins, increases the production of lymphocytes with antiviral properties of interferon alfa and the alpha viral proteins of interferon alfa and infected by the viral proteins and alpha antibodies.

With a combined appointment enhances the action of interferon-alpha, antiviral drugs Acyclovir and zidovudine.

Pharmacokinetics

Suction

After ingestion is well absorbed from the gastrointestinal tract. C_max active substance in the blood plasma is determined after 1-2 hours

Metabolism

Inosine is rapidly metabolized in a cycle typical of purine nucleotides to form uric acid. It is excreted in the urine unchanged and in the form of metabolites within 48 hours. There is no cumulation.

Quickly metabolized. Metabolized similarly to endogenous purine nucleotides to form uric acid, NN-dimethylamino-2-propranolone is metabolized to the N-oxide, and para-acetamido benzoate to o-acylglucuronide. Not detected cumulation of the drug in the body.

Removal

T_1/2 it is 3.5 hours for NN-dimethylamino-2-propranolone and 50 minutes for para-acetamido benzoate. Excreted by the kidneys. The elimination of the drug and its metabolites from the body occurs within 24-48 hours.

Indications for use of the drug

- treatment of influenza and other acute respiratory viral infections;

- infections caused by the Herpes simplex virus types 1, 2, 3 and 4: genital and labial herpes, herpetic keratitis;

- shingles, chicken pox;

- infectious mononucleosis caused by Epstein-Barr virus;

- cytomegalovirus infection;

- Measles severe course;

- HPV infection: laryngeal / vocal cord papillomas (fibrous type), genital papillomavirus infection in men and women, warts;

- molluscum contagiosum.

Dosage and administration

Tablets are taken after meals with a small amount of water.

Recommended daily intake for adults and children aged 3 years and older (with a body weight of 15-20 kg) is 50 mg / kg body weight in 3-4 doses, which is an average for adults - 6-8 tab. / Day, for children - 1/2 tab. per 5 kg of body weight / day.

At severe infectious diseases the dose can be increased individually to 100 mg / kg of body weight / day, divided into 4-6 doses. Maximum Daily Dose for adults 3-4 g / day for children at the age of 3 years and older - 50 mg / kg / day.

The duration of treatment at aboutsevere diseases at adults and children at the age of 3 years and older usually ranges from 5 to 14 days. Treatment should be continued until the clinical symptoms disappear and for 2 more days in the absence of symptoms. If necessary, the duration of treatment can be increased individually under the supervision of a physician.

At chronic recurrent diseases at adults and children at the age of 3 years and older treatment should be continued in several courses of 5-10 days with a break in reception in 8 days.

For maintenance therapy the dose can be reduced to 500-1000 mg / day (1-2 tab.) within 30 days.

At herpes infection adults and children aged 3 years and older the drug is prescribed for 5-10 days until the symptoms of the disease disappear, in the asymptomatic period - 1 tab. 2 times / day for 30 days to reduce the number of relapses.

At human papillomavirus infection for adults the drug is prescribed in 2 tab. 3 times a day, children aged 3 years and older - 1/2 tab. on 5 kg / body weight / day in 3-4 doses for 14-28 days as monotherapy.

At recurrent genital warts for adults the drug is prescribed in 2 tab. 3 times / day children aged 3 years and older - 1/2 tab. at 5 kg / body weight / day in 3-4 doses, either as monotherapy or in combination with surgical treatment for 14-28 days, then with a threefold repetition of the specified course at intervals of 1 month.

Side effect

From the digestive system: nausea, vomiting, epigastric pain, temporary increase in transaminase and alkaline phase activity.

Dermatological reactions: itchiness

From the side of the central nervous system: headache, dizziness, weakness; sometimes drowsiness, insomnia.

From the urinary system: polyuria.

From the musculoskeletal system: joint pain.

Metabolism: exacerbation of gout, increase in the content of uric acid in the blood plasma.

Contraindications to the use of the drug

- urolithiasis disease;

- gout;

- arrhythmias;

- chronic renal failure;

- children's age up to 3 years (body weight up to 15 kg);

- hypersensitivity to the drug.

Use of the drug during pregnancy and lactation

The safety of using izoprinozin during pregnancy and lactation has not been established, so the use of the drug is not recommended.

Application for violations of the liver

After 4 weeks of use, it is advisable to monitor liver function every month (transaminase activity).

Application for violations of kidney function

Contraindicated in chronic renal failure, urolithiasis.

After 4 weeks of use, it is advisable to monitor kidney function every month (creatinine, uric acid levels).

Special notes

Control of laboratory parameters

After 2 weeks of use of izoprinosine, it is recommended to monitor the content of uric acid in serum and urine. After 4 weeks of use, it is advisable to monitor liver and kidney function every month (transaminase activity, creatinine, uric acid levels).

It is necessary to control the level of uric acid in the blood serum when prescribing Isoprinosine in combination with drugs that increase the level of uric acid or drugs that affect kidney function.

Influence on ability to drive motor transport and control mechanisms

There are no special contraindications for driving vehicles or driving machinery.

Overdosage

Data overdose Izoprinozin not provided.

Drug interaction

With simultaneous use of immunosuppressants can reduce the effectiveness of izoprinosin.

Xanthine oxidase inhibitors and uricosuric agents (including diuretics) may contribute to the risk of an increase in the level of uric acid in the blood serum of patients taking Isoprinosine.

Pharmacy sales terms

The drug is available on prescription.

Terms and conditions of storage

List B. The drug should be stored in a dry, dark place, out of the reach of children at a temperature not exceeding 25 ° C.